| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/21/2008 | WO2008020532A1 Novel crystal of 5-aminolevulinic acid phosphate and process for production thereof |
| 02/21/2008 | WO2008020490A1 Artocarpine derivative or artocarpine-like compound, and hair growth/restoration composition, skin-whitening cosmetic composition, pharmaceutical as anti-cancer, antiphlogistic/analgesic, antipyretic or antiallergic agent and pharmaceutical for treatment of pigmented skin lesion each comprising the same |
| 02/21/2008 | WO2008020456A2 Pyrrolo[2,1-c][1,4]benzodiazepine hybrids and a process for the preparation thereof |
| 02/21/2008 | WO2008020455A2 Pyrrolo[2,1-c][1,4]benzodiazepine hybrids and a process for the preparation thereof |
| 02/21/2008 | WO2008020206A2 Fused thiophene derivatives as mek inhibitors |
| 02/21/2008 | WO2008020203A1 Pyridinylquinaz0linamine derivatives and their use as b-raf inhibitors |
| 02/21/2008 | WO2008020180A2 Methods of increasing the sensitivity of cancer cells to dna damage |
| 02/21/2008 | WO2008020045A1 Tetrahydrobenzothiophene derivatives |
| 02/21/2008 | WO2008020039A2 2,5-dihydroxybenzene compounds for treating cancers and hematological dyscrasias |
| 02/21/2008 | WO2008020034A1 Use of 2,5-dihydroxybenzene derivatives for the treatment of hemangiomas or hemangioblastomas |
| 02/21/2008 | WO2008020027A2 2,5-dihydroxybenzene compounds for the treatment of skin cancer |
| 02/21/2008 | WO2008019823A2 Use of certain chemical compounds for the inhibition of the peptidyl-prolyl cis/trans isomerase activity of cyclophilins |
| 02/21/2008 | WO2008019491A1 Inhibition of angiogenesis, tumorigenesis and cathepsin activity using insulin-like growth factor binding protein |
| 02/21/2008 | WO2008000881B1 Glycosylated human alpha interferon muteins, method for obtaining them and use |
| 02/21/2008 | WO2007149512A3 Peptide epoxyketones for pr0teas0me inhibition |
| 02/21/2008 | WO2007149451A3 Cycloalkanopyrrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors |
| 02/21/2008 | WO2007146831A3 Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide |
| 02/21/2008 | WO2007138143A3 Alpha anticholine kinase monoclonal antibodies and their use in analytical techniques for the diagnosis of cancer and the preparation of medicinal products |
| 02/21/2008 | WO2007136692A3 Crystalline forms of 5-chloro-6- (2, 6-difluoro-4- [3- (methylamino) propoxy] phenyl)-n-((1s)-2, 2, 2,-trifluoro-1-methylethyl] [1,2,4] triazolo [1,5-a] pyrimidin-7-amine salts |
| 02/21/2008 | WO2007135078A3 Borrelidin derivatives as antiproliferative agents and angiogenesis inhibitors |
| 02/21/2008 | WO2007129066A8 4- (2,6-dichloro-benzoylamino) -1h-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl) -amide for the treatment of cancer |
| 02/21/2008 | WO2007116923A3 Sez6l2 oncogene as a therapeutic target and prognostic indicator for lung cancer |
| 02/21/2008 | WO2007110243A8 Medicament, cosmetic or food product comprising an indol compound, the use thereof and the method of isolation thereof from sauerkraut |
| 02/21/2008 | WO2007079312A3 Compositions and methods for treating actin-mediated medical conditions |
| 02/21/2008 | US20080045713 Tetrahydroisoquinolinedione derivative intermediates for the hemisynthesis of ecteinascidin or other tetrahydroisoquinolinephenol compounds |
| 02/21/2008 | US20080045709 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors |
| 02/21/2008 | US20080045608 Gene Encoding a Guanine Nucleotide Exchange Factor Binding to Rhoa |
| 02/21/2008 | US20080045603 Methods for treating at least one condition having MT1 receptor, 5HT2B receptor, and L-type calcium channel activity |
| 02/21/2008 | US20080045598 aromatase inhibitors such as N-methyl-N-[2-(4'-nitro benzyloxy)-4-nitrophenyl] methanesulfonamide, used for suppressing aromatase activity expression in breast cancer cells; anticarcinogenic agents |
| 02/21/2008 | US20080045595 Method of treating cancer |
| 02/21/2008 | US20080045594 Use of at Least One Conjugated Triene-Containing Fatty Acid for Preparing a Medicine for Treating Inflammation |
| 02/21/2008 | US20080045589 Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer |
| 02/21/2008 | US20080045584 Use of Docetaxel for Treating Hepatocellular Carcinoma |
| 02/21/2008 | US20080045581 Ppar active compounds |
| 02/21/2008 | US20080045579 Oxazolidine derivatives as PR modulators |
| 02/21/2008 | US20080045571 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| 02/21/2008 | US20080045570 To treat autoimmune, inflammatory, proliferative, hyperproliferative,neurodegenerative or immunologically-mediated diseases; useful for the study of kinases in biological and pathological phenomena; study of intracellular signal transduction pathways mediated by such kinases, and comparative evaluation |
| 02/21/2008 | US20080045563 Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation |
| 02/21/2008 | US20080045561 protein kinase inhibitors such as 5,6-Dimethoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridine, used for the treatment of cancer |
| 02/21/2008 | US20080045559 Tocopherol-modified therapeutic drug compounds |
| 02/21/2008 | US20080045556 4-[2-(4,4-Dimethyl-2-thioxo-1,3-oxazolidin-3-yl)-1,3-thiazol-4-yl]benzonitrile; progesterone receptor (PR); contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, hormone replacement therapy |
| 02/21/2008 | US20080045552 Methods of using selective chemotherapeutic agents for targeting tumor cells |
| 02/21/2008 | US20080045542 anticarcinogenic agent, 3-{4-[3-(2-Fluoro-5-trifluoromethylphenyl)ureido]phenyl}-1H-pyrrole-2-carboxamide, for treating cancer; modulating Protein kinases, relieve the side effect of chemotherapy |
| 02/21/2008 | US20080045538 Nitro and amino substituted topoisomerase agents |
| 02/21/2008 | US20080045535 Prokineticin 2 receptor antagonists |
| 02/21/2008 | US20080045529 Use Of Thienopyrimidines |
| 02/21/2008 | US20080045521 Phenylalanine derivatives |
| 02/21/2008 | US20080045518 3-[4-(4-Bromophenyl)-1,3-thiazol-2-yl]-4-methyl-1,3-oxazolidin-2-one; alternative progesterone receptor modulator; contraception, fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, hormone replacement therapy, eating disorder, synchronizing estrus |
| 02/21/2008 | US20080045517 Such as {(2S)-2-[2-[2-(7-azabicyclo[2.2.1]hept-7-yl)-1,1-dimethyl-2-oxoethyl]-5-(3,5-dimethylphenyl)-6H-thieno[2,3-b]pyrrol-4-yl]propyl}(2-pyridin-4-ylethyl)amine for treating sex hormone related prostate cancer and pre-menopausal breast cancer |
| 02/21/2008 | US20080045514 3-Aryl-6-aryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 02/21/2008 | US20080045501 Pyrido(Hetero or carbo)cyclo)azepinylamine derivatives, e.g., 4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrido[3,4-d][2]benzazepin-2-yl]amino}-benzoic acid; 3-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrido[3,2-d][2]benzazepin-2-yl]-amino}benzoic acid; Aurora kinase inhibitors; anticancer agents |
| 02/21/2008 | US20080045496 Inhibit tyrosine kinase activity of Trk receptors; antiproliferative agents, anticancer agents; cancer, psoriasis or rheumatoid arthritis; N4-pyrazol-5-yl-pyrrolo[2,1-f] [1,2,4]triazine-2,4-diamines |
| 02/21/2008 | US20080045492 Mitotic Kinesin Inhibitors |
| 02/21/2008 | US20080045489 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands |
| 02/21/2008 | US20080045488 Combination of a phytoestrogen compound such as an isoflavone and a progestin such as norgestimate, levonorgestrel, norgestrel, norethindrone, desogestrel, gestodene, dienogest and/or drospirenone; hormone replacement therapy and contraceptives |
| 02/21/2008 | US20080045481 Novel co-crystal |
| 02/21/2008 | US20080045477 Series Of New 4,6-Diamino-1,2-Dihydro-1-Aryl-1,3,5-Triazines, Substituted By An Adamantyl Moiety In The Position 2 Of Triazine-Their Corresponding Salts, Isomers,Steroisomers, Enantiomers, Free Bases And The Complexes Of All The Above With Natural Macromolecules And Their Synthetic Derivatives. |
| 02/21/2008 | US20080045474 Method for treatment of invasive cells |
| 02/21/2008 | US20080045473 Compositions and methods for oligonucleotide formulations |
| 02/21/2008 | US20080045465 Phosphole Derivatives Complexed with Metals, and Pharmaceutical Uses Thereof |
| 02/21/2008 | US20080045460 Treatment of prostate cancer by inhibiting lyn-tyrosine kinase |
| 02/21/2008 | US20080045445 Modulating Notch1 Signaling Pathway for Treating Neuroendocrine Tumors |
| 02/21/2008 | US20080044828 CUDR as biomarker for cancer progression and therapeutic response |
| 02/21/2008 | US20080044493 Agent For Ameliorating The Maximum Passage Time Through Digestive Tract, Agent For Ameliorating Passage Time Through Digestive Tract And Preventive For Colon Cancer |
| 02/21/2008 | US20080044484 Use of polymeric nanoparticles for vaccine delivery |
| 02/21/2008 | US20080044464 Liposome loading with metal ions |
| 02/21/2008 | US20080044463 Bradykinin B2 Receptor Antagonist Peptide From Amphibian Skin |
| 02/21/2008 | US20080044459 Enzymatic debridement therapy for abnormal cell proliferation |
| 02/21/2008 | US20080044452 Drug delivery system for treatment of transitional cell carcinoma |
| 02/21/2008 | US20080044450 Sustained Release Composition |
| 02/21/2008 | US20080044441 Mixed haptenized tumor cells and extracts and methods of treating or screening for cancer |
| 02/21/2008 | US20080044429 Fc.gamma.RIIB-Specific Antibodies and Methods of Use Thereof |
| 02/21/2008 | US20080044425 Polypeptides having phospholipase a2 activity |
| 02/21/2008 | US20080044423 Compounds |
| 02/21/2008 | US20080044421 Methods of using death receptor ligands and CD20 antibodies |
| 02/21/2008 | US20080044415 Hepatocyte growth factor receptor antagonists and uses thereof |
| 02/21/2008 | US20080044413 EphA2 BiTE molecules and uses thereof |
| 02/21/2008 | US20080044412 Single-Domain Antibody Strengthening Fusion Protein Vh-Ldp-Ae |
| 02/21/2008 | US20080044408 Diagnosis, therapy of cancerous diseases; using cancerous disease modifying antibodies |
| 02/21/2008 | US20080044400 Targeted enzyme prodrug therapy |
| 02/21/2008 | US20080044392 Isolation of Stem Cell-Like Cells and Use Thereof |
| 02/21/2008 | US20080044391 Different dendritic cell subsets |
| 02/21/2008 | US20080044386 Protamine-Adenoviral Vector Complexes and Methods of Use |
| 02/21/2008 | US20080044385 Novel Modified Galectin 8 Proteins and Use Thereof |
| 02/21/2008 | US20080044383 increasing engraftment potential of a cell, treating or alleviating a symptom of an immune disorder, tissue injury or cancer by administering to a subject, e.g. human a composition comprising the cells; CD34 and CD44 |
| 02/21/2008 | US20080044376 Cytokine Design |
| 02/21/2008 | US20080044358 Methods for lymph system imaging |
| 02/21/2008 | US20080044354 Compounds Containing a N-Heteroaryl Moiety Linked to Fused Ring Moieties for the Inhibition of Nad(P)H Oxidases and Platelet Activation |
| 02/21/2008 | US20080044350 Optical Imaging Contrast Agents for Imaging Lung Cancer |
| 02/21/2008 | DE102006038252A1 Zubereitung mit marinem Kollagen zur Proteinasehemmung Preparation with marine collagen to Proteinasehemmung |
| 02/21/2008 | CA2661023A1 Prlr-specific antibody and uses thereof |
| 02/21/2008 | CA2660899A1 Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
| 02/21/2008 | CA2660836A1 Triazolotriazines as kinase inhibitors |
| 02/21/2008 | CA2660799A1 Pyrrolo[2,1-c][1,4]benzodiazepine hybrids and a process for the preparation thereof |
| 02/21/2008 | CA2660604A1 Tetrahydrobenzothiophene derivatives |
| 02/21/2008 | CA2660516A1 Treating or preventing cancers over-expressing reg4 or kiaa0101 |
| 02/21/2008 | CA2659585A1 Inhibition of angiogenesis, tumorigenesis and cathepsin activity using insulin-like growth factor binding protein |
| 02/21/2008 | CA2659562A1 Stable lyophilized preparation |
| 02/21/2008 | CA2659425A1 Triazole compounds that modulate hsp90 activity |
| 02/21/2008 | CA2659276A1 2-amido-4-isoxazolyl thiazole compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |